Toggle Nav


Catalog No.
P38α MAPK inhibitor,highly selective and ATP-competitive
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


VX-702 is a selective inhibitor of p38α MAPK with IC50 value ranges from 4 nM to 20 nM [1].

P38 mitogen-activated protein kinases (p38 MAPK), also named as MAPK14, are a class of mitogen-activated protein kinases and play an important role in a signaling cascade controlling cellular responses to cytokines and stress [1-3].

VX-702 is a potent p38α MAPK inhibitor and is designed as for greater affinity and greater selectivity compared with the first reported p38α MAPK inhibitors. When tested with PLTs (platelets), VX-702 caused better maintenance of PLT mitochondrial, functional, structural and metabolic parameters during 7 days storage and restored PLTs properties following an extended interruption of agitation to levels of continuously agitated PLTs [2, 4].

In the isolated perfused rat kidney (IPRK) model, administration of VX-702 at a range of doses between 100 and 600 ng/mL showed linear excretion and the clearance data were consistent with net reabsorption by the kidney. Further, VX-702 was showed not a substrate for renal organic anion and organic cation transport systems [3].

[1].  Kuliopulos, A., R. Mohanlal, and L. Covic, Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004. 92(6): p. 1387-93.
[2].  Skripchenko, A., et al., An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One, 2013. 8(8): p. e70732.
[3].  Tamhane, M., et al., Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Dev Ind Pharm, 2010. 36(3): p. 315-22.
[4].  Wagner, S.J., et al., Amelioration of lesions associated with 24-hour suboptimal platelet storage at 16 degrees C by a p38MAPK inhibitor, VX-702. Vox Sang, 2015. 108(3): p. 226-32.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
Cas No.479543-46-9; 745833-23-2
Solubility≥20.2mg/mL in DMSO
Chemical Name6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide
SDFDownload SDF
Canonical SMILESC1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.


Cell experiment [1]:

Cell lines

blood platelets

Preparation method

The solubility of this compound in DMSO is > 20.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

IC50: 4 to 20 nM


In an ex vivo blood assay primed with LPS, VX-702 dose-dependently inhibited the production of IL-6, IL-1β and TNFα with the IC50 of 59, 122 and 99 ng/ml, respectively. In gel-filtered platelets were prepared from healthy individuals, the activation was completely or partially inhibited by pre-incubation with 1 μM of VX-702 (IC50 = 4 to 20 nM). VX-702 had no effect on platelet aggregation induced by any of the p38 MAPK agonists, such as thrombin, SFLLRN, AYPGKF and collagen, in the presence or absence of platelet inhibitors, such as aspirin, heparin or apyrase. VX-702 did not directly cause platelet aggregation or induce Ca2+ mobilization, or affect basal aggregation induced by shear stress. VX-702 did not significantly affect platelet function and would not be expected to contribute to an elevated risk of hematological side effects in treated patients.

Animal experiment [1]:

Animal models

Mouse collagen-induced arthritis

Dosage form

Oral administration, 0.1 mg/kg, 5 mg/kg, twice daily


VX-702 (0.1 mg/kg twice daily) was equivalent to methotrexate (a commonly used disease modifying antirheumatic drug [DMARD]; also at 0.1 mg/kg) in mouse collagen-induced arthritis. VX-702 (5 mg/kg, twice daily) was found to be equivalent to prednisolone (10 mg/kg, once daily) in the same model, as measured by the percentage inhibition of wrist joint erosion and an inflammation score. Male Sprague Dawley rats with myocardial damage after ischemia-reperfusion injury were randomized to receive either vehicle or VX-702 (5 or 50 mg/kg). The results suggested that phosphor MK2 was markedly increased in the ischemic zone tissue compared with the non-ischemic zone tissue in the vehicle group. This effect was dose-dependently reduced in the VX-702 groups. VX-702 selectively inhibited activation of p38 MAPK after ischemia, with no effects on ERKs and JNKs. The MI/AAR ratio was significantly reduced in the 50-mg/kg group compared with the other two groups. Oral administration of VX-702 reduced myocardial damage after ischemia-reperfusion injury.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome[J]. Current opinion in investigational drugs, 2006, 7(11): 1020-1025.

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK,
Targets p38α          
IC50 4 nM-20 nM          

Quality Control